Respiratory News and Research RSS Feed - Respiratory News and Research

Pneumococcal vaccine prevents illness, reduces severe antibiotic-resistant infections in young children

Pneumococcal vaccine prevents illness, reduces severe antibiotic-resistant infections in young children

The pneumococcal vaccine recommended for young children not only prevents illness and death, but also has dramatically reduced severe antibiotic-resistant infections, suggests nationwide research being presented at IDWeek 2014. [More]
Isis Pharmaceuticals provides update on Phase 2 clinical studies of ISIS-SMN Rx in children with SMA

Isis Pharmaceuticals provides update on Phase 2 clinical studies of ISIS-SMN Rx in children with SMA

Isis Pharmaceuticals, Inc. today provided an update on its ongoing open-label Phase 2 clinical studies of ISIS-SMN Rx in infants and children with spinal muscular atrophy at the 19th International World Muscle Society (WMS) Congress in Berlin, Germany. [More]
Astute Medical to get $30 million from CRG to support commercialization of NephroCheck Test System

Astute Medical to get $30 million from CRG to support commercialization of NephroCheck Test System

Astute Medical, Inc. and CRG today announced that Astute recently achieved a milestone under the terms of its existing term loan agreement with CRG. Under the term loan agreement, CRG will provide up to $30 million to support the commercialization of the NephroCheck Test System. [More]
International Biophysics files patent protection for revolutionary AffloVest

International Biophysics files patent protection for revolutionary AffloVest

International Biophysics Corporation of Austin, Texas announces its filing of U.S. patent protection for its revolutionary AffloVest. The company has also recently confirmed exclusive ownership rights concerning the manufacture, sale and distribution of the AffloVest in its markets. [More]
RPS Diagnostics receives CE mark for FebriDx test

RPS Diagnostics receives CE mark for FebriDx test

RPS Diagnostics, Inc. today announced CE mark of its FebriDx test, clearing the way for sales in the European Union and all countries recognizing the CE mark. [More]
Social status can impact health, happiness even among egalitarian forager-farmers

Social status can impact health, happiness even among egalitarian forager-farmers

In western society, where keeping up with the Joneses — or, better yet, surpassing them — is expected and even encouraged, status matters. So important is it that for many people, physical and emotional wellbeing are directly connected to their place in the social hierarchy. [More]
CSL Behring strengthens global manufacturing capabilities to meet demand for lifesaving therapies

CSL Behring strengthens global manufacturing capabilities to meet demand for lifesaving therapies

CSL Behring today announced a multi-year, $450 million two-site global capacity expansion – the latest in a series of recent production expansions to meet the growing need for its lifesaving and life-improving therapies that are used to treat patients with rare and serious medical disorders around the world. [More]
Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States. [More]
FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant Gram-positive and Gram-negative pathogens, announced today that the United States Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) as well as Fast Track status designation to Nabriva's lead product lefamulin, for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). [More]
Survey finds prevalence of antimicrobial-drug use in U.S. hospitals

Survey finds prevalence of antimicrobial-drug use in U.S. hospitals

A one-day prevalence survey of 183 hospitals found that approximately 50 percent of hospitalized patients included in the survey were receiving antimicrobial drugs, and that about half of these patients were receiving 2 or more antimicrobial drugs, according to a study in the October 8 JAMA, a theme issue on infectious disease. Most antimicrobial use was for infection treatment. [More]
Study finds that hospitalized patients wash their hands infrequently

Study finds that hospitalized patients wash their hands infrequently

Hospital visitors and staff are greeted with hand sanitizer dispensers in the lobby, by the elevators and outside rooms as reminders to wash their hands to stop infections, but just how clean are patients' hands? [More]
Sleeping with dentures increases pneumonia risk in elderly

Sleeping with dentures increases pneumonia risk in elderly

Poor oral health and hygiene are increasingly recognized as major risk factors for pneumonia among the elderly. To identify modifiable oral health-related risk factors, lead researcher Toshimitsu Iinuma, Nihon University School of Dentistry, Japan, and a team of researchers prospectively investigated associations between a constellation of oral health behaviors and incidences of pneumonia in the community-living of elders 85 years of age or older. [More]
Genesis Rehab Services, St. Catherine University to create online occupational therapy assistant program

Genesis Rehab Services, St. Catherine University to create online occupational therapy assistant program

Genesis Rehab Services and St. Catherine University (St. Paul-Minneapolis, Minn.) announced today their partnership to create the first online occupational therapy assistant program to address the rising need for professional occupational therapy assistants throughout the country. [More]
CHLA reports first confirmed case of enterovirus D68 in Los Angeles

CHLA reports first confirmed case of enterovirus D68 in Los Angeles

In September, Children's Hospital Los Angeles physicians predicted it was a matter of when, and not if, Los Angeles children would become infected with Enterovirus EV-D68, commonly referred to as enterovirus D68. On Oct. 1, that day came. CHLA and public health officials announced that a young patient who had been hospitalized at CHLA with a respiratory illness and later experienced partial limb paralysis had tested positive for enterovirus D68. [More]
Researchers reveal 'programmable' antibiotic technique to target drug-resistant microbes

Researchers reveal 'programmable' antibiotic technique to target drug-resistant microbes

The multitude of microbes scientists have found populating the human body have good, bad and mostly mysterious implications for our health. But when something goes wrong, we defend ourselves with the undiscriminating brute force of traditional antibiotics, which wipe out everything at once, regardless of the consequences. [More]
CytoSorbents announces launch of International CytoSorb Treatment Registry

CytoSorbents announces launch of International CytoSorb Treatment Registry

CytoSorbents Corporation, a critical care immunotherapy company using blood purification to treat life-threatening conditions, announced the launch of its International CytoSorb Treatment Registry, established and managed by the Center of Clinical Trials at the University of Jena, Germany. [More]
Study: Benzodiazepine sedatives may increase death risk in patients receiving mechanical ventilation

Study: Benzodiazepine sedatives may increase death risk in patients receiving mechanical ventilation

Sedation is frequently required for mechanically ventilated intensive care unit (ICU) patients to reduce anxiety, provide comfort, and assist in providing optimal respiratory support. [More]
Allakos secures additional $10M investment to expand its development portfolio

Allakos secures additional $10M investment to expand its development portfolio

Allakos Inc. announced today that it has secured an additional $10 million investment from current investors to fund development of an additional therapeutic antibody. [More]
Mymetics' innovative HIV vaccine candidate to enter new preclinical trial

Mymetics' innovative HIV vaccine candidate to enter new preclinical trial

Mymetics Corporation, a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial. [More]
Synapse Biomedical completes enrollment in post-approval study of NeuRx DPS for ALS patients

Synapse Biomedical completes enrollment in post-approval study of NeuRx DPS for ALS patients

Synapse Biomedical Inc. announced today it has completed the enrollment of the post-approval study of its NeuRx DPS System for ALS patients. [More]